Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.
SARS-CoV-2
emerging variants
humoral immunity
receptor-binding domain
vaccine
viral neutralization
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
14 04 2021
14 04 2021
Historique:
received:
19
02
2021
revised:
09
03
2021
accepted:
16
03
2021
pubmed:
3
4
2021
medline:
29
4
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.
Identifiants
pubmed: 33798491
pii: S1931-3128(21)00137-2
doi: 10.1016/j.chom.2021.03.009
pmc: PMC7980225
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Receptors, Virus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
516-521.e3Subventions
Organisme : NIAID NIH HHS
ID : T32 AI074492
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI150747
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Curr Protoc Immunol. 2020 Dec;131(1):e116
pubmed: 33215858
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Med. 2021 Mar 12;2(3):313-320.e4
pubmed: 33554155
Cell Rep. 2021 Jan 12;34(2):108630
pubmed: 33417835
Cell Rep Med. 2021 Jun 15;2(6):100290
pubmed: 33969322
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33211088
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862
pubmed: 30356267
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell. 2021 Apr 1;184(7):1804-1820.e16
pubmed: 33691139
Cell. 2021 Apr 29;184(9):2316-2331.e15
pubmed: 33773105
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33067271
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Med. 2021 Mar 12;2(3):281-295.e4
pubmed: 33589885
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Nat Commun. 2021 Feb 8;12(1):848
pubmed: 33558493
Cell Host Microbe. 2021 Apr 14;29(4):508-515
pubmed: 33789086